Greenwich LifeSciences (GLSI) vs Nature's Sunshine Products (NATR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Greenwich LifeSciences (GLSI) has outperformed Nature's Sunshine Products (NATR) over the past year, gaining 37.0% versus a loss of 16.8%. Over five years, NATR leads with a -18.1% price change compared with -59.5% for GLSI. Nature's Sunshine Products is the larger company by market cap ($219.6 million vs $214.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GLSI | NATR |
|---|---|---|
| Share price | $14.64 | $12.48 |
| Market cap | $214.84M | $219.59M |
| 1-day change | -4.92% | -0.87% |
| YTD return | -26.75% | -41.66% |
| 1-year return | +37.04% | -16.79% |
| 5-year return | -59.46% | -18.09% |
| P/E ratio (TTM) | — | 12.36 |
| Forward P/E | — | 10.15 |
| EPS (TTM) | $-1.53 | $1.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $34.10 | $28.14 |
| 52-week low | $7.78 | $12.31 |
| Distance from 52-week high | -57.08% | -55.65% |
| Analyst consensus | none | none |
| Avg. price target upside | +289.44% | +144.39% |
| Average volume | 138.72K | 159.62K |
| Shares outstanding | 14.68M | 17.60M |
| Employees | — | 806 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GLSI has outperformed NATR by 53.8 percentage points over the past year.
About Greenwich LifeSciences
GLSI stock →Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Health Care · Biotechnology: Pharmaceutical Preparations
About Nature's Sunshine Products
NATR stock →Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. The company distributes general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision; and immune products to support and strengthen the human immune system.
Health Care · Biotechnology: Pharmaceutical Preparations · 806 employees
GLSI vs NATR FAQ
Which is bigger, Greenwich LifeSciences or Nature's Sunshine Products?
Nature's Sunshine Products (NATR) is larger, with a market capitalization of $219.59M compared with $214.84M for Greenwich LifeSciences (GLSI).
Which stock has performed better over the past year, GLSI or NATR?
GLSI returned +37.04% over the past 12 months, compared with -16.79% for NATR (price return, excluding dividends). Past performance does not predict future results.
Are Greenwich LifeSciences and Nature's Sunshine Products in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.